- HHS plan to speed drug research won’t remove ‘self-inflicted’ delays<figure><div><img src="https://imgproxy.divecdn.com/CBRbv7ysPGDg2gR4-a3jhbQNYceSmw-Eq03sjZFRhY4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTk2ODIwNDM5LmpwZ…BioPharma Dive · 19d ago↗ source
- AstraZeneca, Ionis drug fails big heart disease study in major setback<figure><div><img src="https://imgproxy.divecdn.com/BEaA7RlZhiBVZ8rfvBq1gV4dfZ4BC5WOow-17uS8d2o/g:nowe:0:100/c:8192:4628/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlc…BioPharma Dive · 19d ago↗ source
- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s…